Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
10 results
  • Uterine Cancer, Ovarian Cancer, Melanoma, Lung Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Bladder Cancer, Pancreatic Cancer, Liver Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Endometrial Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Breast Cancer, Endometrial Cancer, Bladder Cancer, Liver Cancer

24-666          Phase II

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

  • Endometrial Cancer, Breast Cancer, Gastric (Stomach) Cancer, Ovarian Cancer

22-142          Phase II

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors

  • Endometrial Cancer

22-558          Phase II

A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors

  • Pancreatic Cancer, Lung Cancer, Kidney Cancer, Gastric (Stomach) Cancer, Sarcoma, Colorectal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Prostate Cancer, Endometrial Cancer

23-392          Phase I

A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2

  • Ovarian Cancer, Breast Cancer, Metastatic/Advanced Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer

23-618          Phase I

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

  • Lung Cancer, Melanoma, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer

24-203          Phase I

An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies

  • Endometrial Cancer, Bladder Cancer

22-660          Phase I

An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies with FGFR3 Alterations

  • Ovarian Cancer, Head and Neck Cancer, Endometrial Cancer, Breast Cancer

23-044          Phase II

First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Showing 1 - 10 of 10 results